{"nctId":"NCT00409773","briefTitle":"Ezetimibe/Simvastatin in Patients With Metabolic Syndrome (0653A-107)(COMPLETED)","startDateStruct":{"date":"2007-01"},"conditions":["Hypercholesterolemia","Metabolic Syndrome"],"count":1143,"armGroups":[{"label":"1","type":"OTHER","interventionNames":["Drug: ezetimibe (+) simvastatin","Drug: Comparator: atorvastatin calcium","Drug: Comparator: Placebo (unspecified)"]},{"label":"2","type":"OTHER","interventionNames":["Drug: ezetimibe (+) simvastatin","Drug: Comparator: atorvastatin calcium","Drug: Comparator: Placebo (unspecified)"]},{"label":"3","type":"OTHER","interventionNames":["Drug: ezetimibe (+) simvastatin","Drug: Comparator: atorvastatin calcium","Drug: Comparator: Placebo (unspecified)"]},{"label":"4","type":"OTHER","interventionNames":["Drug: ezetimibe (+) simvastatin","Drug: Comparator: atorvastatin calcium","Drug: Comparator: Placebo (unspecified)"]},{"label":"5","type":"OTHER","interventionNames":["Drug: ezetimibe (+) simvastatin","Drug: Comparator: atorvastatin calcium","Drug: Comparator: Placebo (unspecified)"]}],"interventions":[{"name":"ezetimibe (+) simvastatin","otherNames":["MK0653A","Vytorin®"]},{"name":"Comparator: atorvastatin calcium","otherNames":["Lipitor ®"]},{"name":"Comparator: Placebo (unspecified)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients 18 to 79 years of age with metabolic syndrome and hypercholesterolemia at high risk for coronary heart disease (CHD) with LDL-C above 70 mg/dL or 100 mg/dL depending on their CHD risk category\n\nExclusion Criteria:\n\n* A condition which, in the opinion of the investigator, pose a risk to the patient or interfere with participating in the study\n* Patient is likely to be greater than 20% noncompliant in taking study medications\n* Patients with chronic medical conditions\n* Patients with unstable doses of medications\n* Pregnant or lactating women, women intending to become pregnant\n* Patient is currently receiving prescription therapy with statins or other lipid-altering medications\n* Patient with Type 1 or Type 2 diabetes mellitus that is poorly controlled, newly diagnosed, or is taking new or recently adjusted antidiabetic pharmacotherapy (with the exception of +/- 10 units of insulin)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Low Density Lipoprotein (LDL-C) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.5","spread":null},{"groupId":"OG001","value":"-49.6","spread":null},{"groupId":"OG002","value":"-39.4","spread":null},{"groupId":"OG003","value":"-53.9","spread":null},{"groupId":"OG004","value":"-46.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Cholesterol(mg/dL) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.5","spread":null},{"groupId":"OG001","value":"-33.7","spread":null},{"groupId":"OG002","value":"-28.3","spread":null},{"groupId":"OG003","value":"-37.3","spread":null},{"groupId":"OG004","value":"-32.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Triglyceride (TG) (mg/dL) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-21.7","spread":null},{"groupId":"OG001","value":"-23.3","spread":null},{"groupId":"OG002","value":"-27.5","spread":null},{"groupId":"OG003","value":"-29.5","spread":null},{"groupId":"OG004","value":"-30.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":null},{"groupId":"OG001","value":"6.8","spread":null},{"groupId":"OG002","value":"5.6","spread":null},{"groupId":"OG003","value":"8.8","spread":null},{"groupId":"OG004","value":"4.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non- High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.5","spread":null},{"groupId":"OG001","value":"-43.8","spread":null},{"groupId":"OG002","value":"-36.5","spread":null},{"groupId":"OG003","value":"-48.3","spread":null},{"groupId":"OG004","value":"-41.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Very Low Density Lipoprotein Cholesterol (VLDL-C) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.7","spread":null},{"groupId":"OG001","value":"-18.3","spread":null},{"groupId":"OG002","value":"-21.6","spread":null},{"groupId":"OG003","value":"-23.4","spread":null},{"groupId":"OG004","value":"-22.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein- B (Apo-B) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.9","spread":null},{"groupId":"OG001","value":"-37.2","spread":null},{"groupId":"OG002","value":"-31.9","spread":null},{"groupId":"OG003","value":"-41.1","spread":null},{"groupId":"OG004","value":"-35.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein-A1 (Apo-A1) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":null},{"groupId":"OG001","value":"3.2","spread":null},{"groupId":"OG002","value":"1.0","spread":null},{"groupId":"OG003","value":"3.0","spread":null},{"groupId":"OG004","value":"1.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total-Cholesterol: High Density Lipoprotein-Cholesterol (Total-C:HDL- C) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-28.1","spread":null},{"groupId":"OG001","value":"-36.9","spread":null},{"groupId":"OG002","value":"-31.5","spread":null},{"groupId":"OG003","value":"-41.2","spread":null},{"groupId":"OG004","value":"-35.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (LDL-C: HDL-C) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.8","spread":null},{"groupId":"OG001","value":"-51.8","spread":null},{"groupId":"OG002","value":"-42.1","spread":null},{"groupId":"OG003","value":"-56.6","spread":null},{"groupId":"OG004","value":"-48.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Apolipoprotein-B: Apolipoprotein-A1 (Apo-B:Apo-A1) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-27.4","spread":null},{"groupId":"OG001","value":"-38.4","spread":null},{"groupId":"OG002","value":"-32.0","spread":null},{"groupId":"OG003","value":"-41.9","spread":null},{"groupId":"OG004","value":"-36.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol: High Density Lipoprotein Cholesterol (Non-HDL-C:HDL-C) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-34.7","spread":null},{"groupId":"OG001","value":"-46.2","spread":null},{"groupId":"OG002","value":"-39.2","spread":null},{"groupId":"OG003","value":"-51.2","spread":null},{"groupId":"OG004","value":"-43.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients With Atherosclerotic Vascular Disease (AVD)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.1","spread":null},{"groupId":"OG001","value":"-48.7","spread":null},{"groupId":"OG002","value":"-36.9","spread":null},{"groupId":"OG003","value":"-56.1","spread":null},{"groupId":"OG004","value":"-45.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 6 in Patients Without Atherosclerotic Vascular Disease (AVD)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.3","spread":null},{"groupId":"OG001","value":"-50.1","spread":null},{"groupId":"OG002","value":"-40.3","spread":null},{"groupId":"OG003","value":"-53.2","spread":null},{"groupId":"OG004","value":"-46.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in High-Sensitivity C-reactive (Hs-CRP) (mg/dL) at Week 6","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.8","spread":null},{"groupId":"OG001","value":"-17.2","spread":null},{"groupId":"OG002","value":"-22.4","spread":null},{"groupId":"OG003","value":"-27.6","spread":null},{"groupId":"OG004","value":"-30.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4},"commonTop":["Any Musculoskeletal And Connective Tissue Disorders","Any Gastrointestinal Disorders","Any Nervous System Disorders","Diarrhoea","Myalgia"]}}}